Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however differences in treatment duration, 6 monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) comparisons. We introduce the AE burden score (AE(sc)) to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruppert, Amy S., Booth, Allison M., Ding, Wei, Bartlett, Nancy L., Brander, Danielle M., Coutre, Steven, Brown, Jennifer R., Nattam, Sreenivasa, Larson, Richard A., Erba, Harry, Litzow, Mark, Owen, Carolyn, Kuzma, Charles S., Abramson, Jeremy S., Little, Richard F., Smith, Scott E., Stone, Richard M., Byrd, John C., Mandrekar, Sumithra J., Woyach, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744070/
https://www.ncbi.nlm.nih.gov/pubmed/34274940
http://dx.doi.org/10.1038/s41375-021-01342-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744070/
https://www.ncbi.nlm.nih.gov/pubmed/34274940
http://dx.doi.org/10.1038/s41375-021-01342-x

Ejemplares similares